This HTML5 document contains 84 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n24http://linked.opendata.cz/resource/drugbank/drug/DB00846/identifier/pubchem-substance/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00846/identifier/kegg-drug/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00846/identifier/drugbank/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/mesh/concept/
n7http://linked.opendata.cz/resource/drugbank/company/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00846/identifier/national-drug-code-directory/
n4http://linked.opendata.cz/resource/drugbank/mixture/
n9http://bio2rdf.org/drugbank:
n28http://linked.opendata.cz/resource/drugbank/drug/DB00846/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00846/identifier/wikipedia/
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00846/identifier/pharmgkb/
n11http://www.drugs.com/cdi/
n18http://www.rxlist.com/cgi/generic2/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00846/identifier/pubchem-compound/
n27http://linked.opendata.cz/resource/atc/
n26http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00846
rdf:type
n3:Drug
n3:description
A corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive. (From Martindale, The Extra Pharmacopoeia, 30th ed, p733)
n3:dosage
n16:271B4B87-363D-11E5-9242-09173F13E4C5 n16:271B4B88-363D-11E5-9242-09173F13E4C5 n16:271B4B85-363D-11E5-9242-09173F13E4C5 n16:271B4B86-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly dry, scaling localized lesions
n3:manufacturer
n7:271B4B7E-363D-11E5-9242-09173F13E4C5 n7:271B4B7F-363D-11E5-9242-09173F13E4C5 n7:271B4B80-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00846 n17:DB00846
dcterms:title
Flurandrenolide
adms:identifier
n13:Fludroxycortide n15:PA164750513 n21:D00328 n22:55515-052-15 n23:DB00846 n24:46505159 n25:15209 n28:14475
n3:mechanismOfAction
Flurandrenolide is a topical corticosteroid. It is normally applied to a plastic tape called Cordran. Cordran is primarily effective because of its anti-inflammatory, antipruritic, and vasoconstrictive actions. Flurandrenolide, which is slowly released from the Cordran tape, binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. Cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In another words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Like other glucocorticoid agents Fluocinolone acetonide acts as a physiological antagonist to insulin by decreasing glycogenesis (formation of glycogen). It also promotes the breakdown of lipids (lipolysis), and proteins, leading to the mobilization of extrahepatic amino acids and ketone bodies. This leads to increased circulating glucose concentrations (in the blood). There is also decreased glycogen formation in the liver.
n3:packager
n7:271B4B7C-363D-11E5-9242-09173F13E4C5 n7:271B4B7D-363D-11E5-9242-09173F13E4C5 n7:271B4B7A-363D-11E5-9242-09173F13E4C5 n7:271B4B7B-363D-11E5-9242-09173F13E4C5 n7:271B4B79-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Topical corticosteroids can be absorbed from normal intact skin. They are metabolized primarily in the liver and then excreted in the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
n3:synonym
Fludroxicortida Cordran Fludrossicortide Fludroxycortid Fludroxicortide Flurandrenolide Flurandrenolone Fludroxycortidum Fludroxycortide
n3:toxicity
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary- adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients
n3:mixture
n4:271B4B77-363D-11E5-9242-09173F13E4C5 n4:271B4B78-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Corticosteroids are bound to plasma proteins in varying degrees.
n3:synthesisReference
Casas-Campillo, C.; U.S. Patent 3,119,748; January 28, 1964; assigned to Syntex Corporation, Panama. Ringold, H.J., Zderic, J.A., Djerassi, C. and Bowers, A.; U.S. Patent 3,126,375; March 24, 1964; assigned to Syntex Corporation, Panama.
n19:hasConcept
n20:M0008644
foaf:page
n11:flurandrenolide-cream.html n18:fluran.htm
n3:IUPAC-Name
n5:271B4B8D-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4B93-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4B92-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4B8F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4B90-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4B91-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4B8B-363D-11E5-9242-09173F13E4C5 n5:271B4BA3-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B4B8C-363D-11E5-9242-09173F13E4C5 n5:271B4BA5-363D-11E5-9242-09173F13E4C5 n5:271B4B89-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B4B8A-363D-11E5-9242-09173F13E4C5
n26:hasATCCode
n27:D07AC07
n3:H-Bond-Acceptor-Count
n5:271B4B99-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B4B9A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4B94-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4B95-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4B97-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4B96-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4B98-363D-11E5-9242-09173F13E4C5
n3:absorption
Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to those of systemically administered corticosteroids
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
1524-88-5
n3:category
n3:containedIn
n6:271B4B83-363D-11E5-9242-09173F13E4C5 n6:271B4B84-363D-11E5-9242-09173F13E4C5 n6:271B4B81-363D-11E5-9242-09173F13E4C5 n6:271B4B82-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4B9F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4BA1-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4BA2-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B4BA4-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4B9E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4B9D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4BA0-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4B8E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B4B9B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4B9C-363D-11E5-9242-09173F13E4C5